drugset / Trial / NCT03655691

ET-01 in Subjects With Lateral Canthal Lines, LCL-207

NCT03655691 ↗

Phase 2 Completed 79 enrolled Eirion Therapeutics Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).

Timeline

Start
2018-08-16
Primary completion
2018-11-09
Completion
2019-04-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic — Topical

Indications